Whitepaper: The Pharmaceutical industry and the UK Bribery Act

uk bribery act, pharma industry, thomson reuters, pharma compliance, cee, europe

 

The UK Bribery Act (UKBA) puts particular pressure on pharmaceutical companies. Already operating in a highly regulated environment, due to the nature of their business pharma companies are active and associate with third parties in various locales around the world, and often have many bureaucratic hurdles to overcome. This paper discusses the particular vulnerabilities of the industry in light of the UKBA.

Discussed in the whitepaper:

  • The UK Bribery Act Casts A Wide Net
  • The Relevance To The Pharmaceutical Industry
  • Promotional Activity
  • Ways A Prudent Company Can Protect Itself

Download whitepaper

Thomson Reuters is Silver Sponsor for the upcoming Pharma Compliance CEE conference happening in Istanbul this 4-5 June 2014.  For more information, click here